CLINICAL_TRIALS
research
· 2026-01-20
Clinical Trial Update: A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD [Phase 3]
Summary
A phase 3 clinical trial evaluating Del-brax (AOC-1020) for facioscapulohumeral muscular dystrophy is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Avidity Biosciences, Inc. | Conditions: Facioscapulohumeral Muscular Dystrophy, FSHD | Phase 3 | Status: RECRUITING